Sath Shukla - Feb 1, 2022 Form 4 Insider Report for Spero Therapeutics, Inc. (SPRO)

Role
Chief Financial Officer
Signature
/s/ Tamara Joseph, Attorney-in-Fact for Sath Shukla
Stock symbol
SPRO
Transactions as of
Feb 1, 2022
Transactions value $
$0
Form type
4
Date filed
2/3/2022, 03:19 PM
Previous filing
Aug 30, 2021
Next filing
Aug 30, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRO Common Stock Award $0 +38K +157.95% $0.00 62.1K Feb 1, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRO Stock Option (Right to Buy) Award $0 +53.2K $0.00 53.2K Feb 1, 2022 Common Stock 53.2K $11.18 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2023, subject to the Reporting Person's continued service through the applicable vesting date.
F2 Consists of 62,081 RSUs held by the Reporting Person.
F3 The shares underlying this option vest as to 25% on February 1, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

Remarks:

Exhibit 24.1 - Power of Attorney